CEL-SCI Corporation (NYSEMKT:CVM) reported an operating loss of ($6,226,435) for the quarter ended March 31, 2014 versus an operating loss of ($4,239,824) for the quarter ended March 31, 2013. CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is -2.52%. On last trading day company shares ended up $1.16. Analysts mean target price for the company is $7.00. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is -16.25%.
Theravance (NASDAQ:THRX) major shareholder Plc Glaxosmithkline purchased 317,770 shares of the company’s stock on the open market in a transaction that occurred on Friday, May 9th. The shares were purchased at an average price of $8,544,840.00 per share, for a total transaction of $2,715,293,806,800.00. Theravance Inc. (NASDAQ:THRX) shares advanced 6.73% in last trading session and ended the day on $28.86. THRX return on assets is -37.40%.Theravance Inc. (NASDAQ:THRX) quarterly performance is -24.84%.
On May 14, 2014, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued a press release announcing the appointment of Christopher Bowden, M.D., as the Company’s chief medical officer commencing May 13, 2014. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares moved up 9.36% in last trading session and was closed at $35.97, while trading in range of $32.79 – $36.28. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) year to date (YTD) performance is 50.19%.
Prima BioMed Ltd (NASDAQ:PBMD) said its experimental lead treatment improved survival in some ovarian cancer patients without the disease worsening. Prima Biomed Ltd. (NASDAQ:PBMD) ended the last trading day at $1.25. Company weekly volatility is calculated as 10.18%. Prima Biomed Ltd. (NASDAQ:PBMD) showed a positive weekly performance of 25.00%.
Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its quarterly earnings results on Monday. The company reported ($0.85) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $0.48, American Banking and Market News reports. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares advanced 5.44% in last trading session and ended the day on $35.26. RARE return on assets is -78.30%.Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) quarterly performance is -21.26%.